Omeros (NASDAQ:OMER) Upgraded by RODMAN&RENSHAW to Strong-Buy Rating

RODMAN&RENSHAW upgraded shares of Omeros (NASDAQ:OMER) to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

OMER has been the subject of a number of other reports. StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a report on Tuesday. Rodman & Renshaw began coverage on Omeros in a report on Thursday. They issued a “buy” rating and a $9.00 price target for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Thursday. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a report on Thursday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Omeros presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Omeros Stock Up 2.0 %

NASDAQ OMER traded up $0.14 during trading on Thursday, hitting $7.09. The stock had a trading volume of 1,323,976 shares, compared to its average volume of 462,819. The company has a market capitalization of $410.84 million, a PE ratio of -2.89 and a beta of 1.47. The firm has a 50 day moving average price of $4.08 and a 200 day moving average price of $4.07. Omeros has a twelve month low of $1.38 and a twelve month high of $7.51.

Institutional Trading of Omeros

Several large investors have recently bought and sold shares of OMER. BNP Paribas Financial Markets boosted its stake in shares of Omeros by 75.5% during the first quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 12,951 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in Omeros during the first quarter worth about $85,000. Vanguard Group Inc. lifted its position in Omeros by 2.6% during the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after buying an additional 81,348 shares during the period. Comerica Bank lifted its position in Omeros by 20.0% during the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 5,000 shares during the period. Finally, Cypress Capital Group lifted its position in Omeros by 40.0% during the second quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 10,000 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.